Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Safety issues in isotretinoin therapy
Autore:
Hanson, N; Leachman, S;
Indirizzi:
Univ Utah, Hlth Sci Ctr, Dept Dermatol, Huntsman Canc Inst, Salt Lake City, UT 84112 USA Univ Utah Salt Lake City UT USA 84112 Inst, Salt Lake City, UT 84112 USA
Titolo Testata:
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY
fascicolo: 3, volume: 20, anno: 2001,
pagine: 166 - 183
SICI:
1085-5629(200109)20:3<166:SIIIT>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
13-CIS RETINOIC ACID; LOW-DOSE ISOTRETINOIN; PREMATURE EPIPHYSEAL CLOSURE; INFLAMMATORY-BOWEL-DISEASE; SQUAMOUS-CELL CARCINOMA; SOY PROTEIN ISOLATE; NEURAL CREST CELLS; 13-CIS-RETINOIC ACID; ORAL ISOTRETINOIN; ACNE-VULGARIS;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
239
Recensione:
Indirizzi per estratti:
Indirizzo: Leachman, S Univ Utah, Hlth Sci Ctr, Dept Dermatol, Huntsman Canc Inst, 2000 Circle Hope,Rm 5242, Salt Lake City, UT 84112 USA Univ Utah 2000 Circle Hope,Rm 5242 Salt Lake City UT USA 84112
Citazione:
N. Hanson e S. Leachman, "Safety issues in isotretinoin therapy", SEM CUT M S, 20(3), 2001, pp. 166-183

Abstract

Isotretinoin (Accutane, Roche Laboratories Inc, Nutley, NJ) is an important drug, not only for the treatment of severe acne, but also for other diagnoses and in chemoprevention settings. Because the use of isotretinoin is increasing, it is important for physicians to be aware of the adverse events,toxicities, and management issues related to its use. The most important issue is that of congenital defects, which has resulted in new pregnancy prevention policies and programs implemented by the manufacturer. A relativelynew concern is that of depression associated with isotretinoin use, also resulting in new policies placed by the manufacturer and the FDA. The most common adverse effects observed during treatment are mucocutaneous and ocular in nature, but laboratory abnormalities and effects in the nervous, musculoskeletal, gastrointestinal, pulmonary, hematologic, and other systems arealso described. Additionally, potential drug interactions, follow-up, and toxicity prevention measures are discussed. Copyright (C) 2001 by W.B. Saunders Company.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 22:58:43